09/12/2026
Incorporating Metabolic Oncology therapy into your conventional cancer treatment plan. And how to talk to the oncologist.
Many people reading this will have a family member who is already deep into conventional chemotherapy. Standard chemo initially targets the "bulk tumor" population but will promote proliferation of cancer stem cells — the very cells responsible for relapse and metastasis.
So, What do you say to someone in that situation? What can be done alongside conventional treatment to limit that damage and address the stem cells that chemo misses?
This is one of the most difficult—and most important—clinical realities to confront.
By the time most patients are diagnosed, they are already on a defined path: surgery, chemotherapy, radiation, or immunotherapy. These treatments can shrink tumors, relieve symptoms, and in some cases prolong survival. So, the question is not whether to reject conventional therapy outright, but how to think more clearly about what it does—and what it does not do.
The unfortunate truth:
Chemotherapy is designed to target rapidly dividing cells, which works—only to a point.
Cancer is not a uniform mass or bulk. It is a hierarchical ecosystem of a critical population:
→ Cancer stem cells (CSCs)
Stem cells behave very differently:
They divide slowly (or intermittently).
They are metabolically flexible.
They are resistant to oxidative and cytotoxic stress.
They regenerate the tumor after the chemo treatment.
So, while chemotherapy may debulk the tumor, it will enrich the stem cell populations. Chemo creates a post-treatment microenvironment that favors cancer cell regrowth.
This is a well-described biological phenomenon.
Most critically, chemotherapy induces neutropenia and depletes the key cancer-fighting components of the immune system—including natural killer cells, T cells, and monocytes—cells that are critical for fighting to eliminate cancer cells. This creates a clear therapeutic paradox.
Conventional oncologists may not know how to address the metabolic, immune and stem-cell biology of cancer.
So what do you say to the oncologist who is being paid to use chemo? You do not say: “Stop chemotherapy.”
Instead, you must reframe it to asking "what can be done alongside chemotherapy"?
You are, in effect, asking:
How do we make the environment as hostile as possible for cancer stem cells to grow—while chemotherapy initially reduces tumor bulk? The goal is not to “replace” chemotherapy—but limit the amount of chemo sessions before damage to non-cancer cells destroys the immune system. And to target the vulnerabilities it leaves behind: stem cells.
1. Penetrating the metabolic backbone:
Cancer stem cells rely heavily on mitochondrial function. The mitochondria are the "powerhouse" inside all cells.
I. A metabolic foundation is critical to protect mitochondria:
Metformin → AMPK activation, mTOR inhibition, reduces insulin signaling.
Berberine → complementary AMPK activation, glucose suppression
Together, they:
Lower systemic glucose and insulin (fuel + signaling).
Create a hostile energetic environment for cancer cell growth.
Reduce the "adaptive capacity" of the CSCs.
II. Directly target the mitochondrial function (to achieve cancer stem cell vulnerability)
Chemotherapy ignores this axis.
Agents that impact mitochondria function to affect CSCs:
Doxycycline
→ Inhibits mitochondrial ribosomes
→ Disrupts oxidative phosphorylation
→ Targets CSC energy production
This is one of the most important complementary strategies.
III. Disrupt cytoskeletal (cell membrane) integrity. CSCs rely on signaling pathways that are distinct from the bulk tumor cells:
Mebendazole
→ Disrupts microtubules.
→ Interferes with cell division and intracellular transport.
→ Shows activity against resistant cell populations.
4. Changes the tumor microenvironment.
IV. Chemotherapy creates a pro-inflammatory, pro-growth rebound state. Blunting that inflammatory response is critical:
Propranolol
→ Reduces adrenergic signaling
→ Decreases stress-mediated tumor progression
→ Reduces metastasis signaling with
Melatonin
→ Antioxidant and mitochondrial regulator
→ Supports circadian control (that is disrupted in cancer)
→ Enhances treatment tolerance
V. Use phytochemicals to apply distributed pressure to CSCs:
These are strong multi-target modulators.
(One BIG caution: not all supplements are effective or safe - some contain toxic carcinogenic additive that can cause liver injury. Follow the "exact product links, and dosing" in the updated protocol of Sweetsoozie's Holistic Health, pinned up top of the page:
Curcumin
Epigallocatechin gallate (ECGC)
Resveratrol
Sulforaphane
They will collectively:
Modulate NF-κB, STAT3, and inflammatory signaling
Interfere with stemness pathways
Enhance oxidative stress selectively in tumor cells
VI. Diet is not optional—it is foundational
This is where most patients and oncologists unknowingly undermine everything. They consume sweets and juices and Ensure type products during chemo, instead of fasting.
A high-carbohydrate, high-insulin diet:
Fuels glycolysis.
Activates growth signaling (insulin/IGF-1).
Counteracts AMPK activation.
Promotes CSC cancer survival.
A low-glycemic, ketogenic metabolically controlled diet:
Reduces glucose availability.
Lowers insulin-driven signaling.
Enhances the effect of metformin/berberine.
Pushes cancer cells toward metabolic stress.
Without dietary alignment, the entire metabolic strategy is significantly weakened.
Instead of asking:
“Is chemotherapy enough?”
You ask:
“What is chemotherapy missing, and how do we systematically close those gaps? I want to continue the treatment plan you’ve outlined but am interested in adding supportive strategies that may improve outcomes and reduce toxicity." You will later stop after 3 chemo treatments, on your own, to reduce the damage to non-cancerous body cells and preserve immune cells.
Most oncologists will react defensively as they sense a challenge to their authority or their treatment plan (that will limit financial income).
Frame It as “Adjunctive,” Not “Alternative”. Example:
“I’ve been reading about adjunctive metabolic approaches—particularly the use of well-known drugs that may have anti-cancer effects. I’d like your input on whether any of these could be layered alongside your standard therapy. Would you be comfortable discussing one or two low-risk agents, such as metformin or Doxycycline? If this isn’t something you’re comfortable managing, I completely understand. But I’d still like to coordinate anything I can do so it remains safe alongside your treatment.” This preserves the relationship.
If the oncologist declines:
Seek a physician experienced in integrative/repurposed approaches.
Connect the communication between both providers.
Medical Disclaimer: The discussion of repurposed medications and nutraceuticals here is intended to review the scientific literature and does not constitute a recommendation for self-treatment. Decisions regarding the use of off-label therapies should be made in consultation with a qualified healthcare professional familiar with the patient’s medical history and current treatment plan.
